ChemoCentryx Inc. (NASDAQ:CCXI) shares were down 2.8% during trading on Thursday . The stock traded as low as $4.42 and last traded at $4.52, with a volume of 93,821 shares. The stock had previously closed at $4.65.

A number of analysts recently issued reports on the company. Zacks Investment Research raised ChemoCentryx from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Wednesday, April 27th. Cowen and Company reissued a “hold” rating on shares of ChemoCentryx in a research report on Thursday, May 19th.

The firm’s market capitalization is $201.08 million. The stock has a 50 day moving average price of $4.88 and a 200 day moving average price of $3.87.

ChemoCentryx (NASDAQ:CCXI) last announced its quarterly earnings data on Tuesday, May 10th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.27) by $0.07. On average, analysts predict that ChemoCentryx Inc. will post ($0.35) earnings per share for the current fiscal year.

In other news, Director Thomas A. Edwards bought 50,000 shares of the stock in a transaction on Tuesday, May 17th. The shares were bought at an average price of $4.05 per share, with a total value of $202,500.00. Following the completion of the acquisition, the director now owns 91,977 shares of the company’s stock, valued at $372,506.85. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas A. Edwards bought 25,000 shares of the stock in a transaction on Monday, May 16th. The stock was purchased at an average cost of $4.05 per share, for a total transaction of $101,250.00. Following the acquisition, the director now directly owns 41,977 shares of the company’s stock, valued at approximately $170,006.85. The disclosure for this purchase can be found here.

ChemoCentryx, Inc (ChemoCentryx) is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing orally-administered therapeutics to treat orphan and rare diseases, autoimmune diseases, inflammatory disorders and cancer. It targets the chemoattractant system, which is a network of molecules, including chemokine ligands and their associated receptors, as well as related chemoattractant receptors.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.